Plasmodium Immunotherapy for Advanced Cancers
The purpose of this study is to evaluate the safety of Plasmodium immunotherapy and preliminarily evaluate the effectiveness of Plasmodium immunotherapy for advanced cancers.The treatment will last 3-6 months from the day of successful infection and will be terminated by antimalarial drugs.
| Condition(s) | Advanced Cancers |
|---|---|
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Study type | Interventional |
| Summary | The purpose of this study is to evaluate the safety of Plasmodium immunotherapy and preliminarily evaluate the effectiveness of Plasmodium immunotherapy for advanced cancers.The treatment will last 3-6 months from the day of successful infection and will be terminated by antimalarial drugs. |
| Who can participate | Inclusion Criteria: * 18-70 years of age, male or female. * Patients with advanced cancer confirmed by histopathology and imaging; and imaging lesions of the tumor are clear and measurable, including but not limited to colon cancer, breast cancer, liver cancer, lung cancer, gastric cancer,sarcoma and other solid tumors (except for nasopharyngeal carcinoma, lymphatic cancer, cervical cancer and melanoma). * The time interval of the termination of chemotherapy (including interventional chemotherapy) or radiotherapy is at least 3 months for patients who had received chemotherapy (including interventional chemotherapy) or radiotherapy; at least 5 half-life for patients who had received targeted drug therapy (the half-life of targeted drug is according to the drug instructions); * All the patie |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Lead sponsor | CAS Lamvac Biotech Co., Ltd. |
| Locations | Guangzhou, Guangdong, China |
| Start date | 2017-11-23 |
| NCT ID | NCT03375983 |
| Official listing | https://clinicaltrials.gov/study/NCT03375983 |